Congenital Infections (Cytomegalovirus - HHV-5)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Congenital cytomegalovirus (CMV, HHV-5) means infection acquired before birth. Most infected babies have no signs at birth and many remain healthy. Some develop hearing loss later; infants with symptomatic disease may have poor growth, petechiae, jaundice, an enlarged liver/spleen, or brain and eye injury. Early testing and continued hearing/developmental follow-up matter even after a normal newborn hearing screen.

Clinical Definition

Congenital CMV is transplacental infection by HHV-5, an enveloped double-stranded DNA herpesvirus. Maternal primary infection, reinfection with another strain, or reactivation can transmit infection. It is the most common congenital viral infection and an important non-genetic cause of sensorineural hearing loss. Most newborns lack obvious signs; symptomatic disease classically combines microcephaly, periventricular calcifications, hearing loss, petechiae and hepatosplenomegaly. Viral cytopathic injury and inflammation damage developing tissues. Confirm infection virologically within the first 21 days, rather than diagnosing it from this clinical pattern alone.

Inciting Event

  • Primary maternal CMV infection can transmit at any stage of pregnancy. Transmission becomes more frequent later in gestation, but early fetal infection carries the greatest risk of major developmental injury.

  • Nonprimary maternal infection includes reactivation and reinfection with a different strain; preexisting antibodies do not eliminate fetal risk.

  • Exposure to CMV-infected bodily fluids such as saliva or urine from young children triggers maternal infection.

  • Transplacental passage of CMV from mother to fetus is the key event causing congenital infection.

Latency Period

  • Congenital infection occurs in utero. About 10% of infected infants have recognizable signs at birth; many have no neonatal illness.

  • Fetal infection occurs weeks to months before delivery, with a variable incubation period depending on timing of maternal infection.

  • Some infants remain asymptomatic at birth but develop sequelae such as sensorineural hearing loss months to years later.

  • There is no fixed neonatal incubation interval that diagnoses congenital infection. Infection acquired during delivery or through breast milk is perinatal/postnatal CMV, a separate timing category.

Diagnostic Delay

  • Lack of specific symptoms at birth leads to missed or delayed diagnosis in many infants.

  • Overlap of clinical features with other congenital infections or genetic disorders causes diagnostic confusion.

  • Failure to obtain urine/saliva PCR within 21 days can prevent later distinction between congenital and postnatal infection. Test promptly when hearing-screen or clinical findings raise concern.

  • Later hearing loss may trigger retrospective testing of a stored newborn dried blood spot. A positive result can establish congenital timing, but a negative result does not exclude infection.

  • Low clinical suspicion in mothers without known CMV exposure contributes to underdiagnosis.

Clinical Presentation


Signs & Symptoms

  • Fetal growth restriction and low birth weight are clues in symptomatic disease, not findings present in most infected newborns.

  • Jaundice and hepatosplenomegaly reflect systemic infection.

  • Sensorineural hearing loss can be unilateral or bilateral, present at birth or delayed, fluctuating or progressive; passing the newborn screen does not exclude later loss.

  • Seizures and lethargy indicate CNS involvement.

  • Petechiae and purpura result from thrombocytopenia.

History of Present Illness

  • Newborns may present with jaundice, petechiae, and hepatosplenomegaly shortly after birth.

  • Microcephaly may already be present at birth; impaired head growth or developmental delay may become evident later.

  • Hearing loss may emerge later, whereas chorioretinitis can already be present neonatally and warrants appropriate eye evaluation.

  • Some infants have a history of intrauterine growth restriction and prematurity.

  • Neurologic symptoms such as seizures and hypotonia may develop as the disease progresses.

Past Medical History

  • Maternal history of febrile illness or mononucleosis-like syndrome during pregnancy may be present.

  • A previous fetal loss or congenital anomaly is nonspecific and cannot establish maternal or fetal CMV infection. Review actual prenatal test results and imaging.

  • Review maternal primary or nonprimary infection and prenatal findings; absence of a maternal illness or known exposure does not exclude congenital CMV.

  • History of immunosuppressive conditions or therapies in the mother may predispose to reactivation.

  • No specific past medical history is required in the infant for congenital CMV diagnosis.

Family History

  • No classic heritable pattern is associated with congenital CMV infection.

  • A family history of hearing loss raises genetic alternatives; it does not by itself identify CMV. Assess neonatal virology, phenotype and family history together.

  • No known familial syndromes directly linked to CMV infection exist.

  • Congenital CMV can occur in more than one pregnancy through primary or nonprimary maternal infection; it is not a Mendelian inherited disorder and does not require repeated primary seroconversion.

  • Genetic predisposition to severe CMV disease has not been clearly established.

Physical Exam Findings

  • Petechiae or purpura suggest thrombocytopenia in symptomatic congenital CMV; many infected infants have a normal skin examination.

  • Hepatosplenomegaly is a clue to symptomatic systemic involvement rather than a universal finding.

  • Measure head circumference for microcephaly. Periventricular calcifications are an imaging finding, not detectable on physical examination.

  • Jaundice and conjugated hyperbilirubinemia may be present from neonatal hepatitis.

  • Chorioretinitis can be detected on fundoscopic exam indicating ocular involvement.

Diagnostic Workup


Diagnostic Criteria

Confirm congenital CMV by detecting virus in a specimen obtained within the first 21 days of life. Urine PCR is confirmatory; a positive saliva PCR requires urine confirmation within this window. Collect saliva more than 1 hour after breastfeeding to reduce milk contamination. Blood PCR is less sensitive, and a negative blood or stored newborn dried-blood-spot PCR cannot exclude infection. IgG/IgM serology is not diagnostic: maternal IgG crosses the placenta and neonatal IgM is unreliable. Later urine/saliva positivity alone cannot distinguish congenital from postnatal acquisition; imaging supports disease assessment but is not virologic confirmation.

Pathophysiology


Key Mechanisms

  • CMV replication causes cytopathic injury in developing organs. A classic histologic clue is an enlarged infected cell with an owl-eye intranuclear inclusion and surrounding halo; biopsy is not the routine neonatal diagnostic test.

  • CMV-induced inflammation causes tissue damage and disrupts normal fetal development, resulting in microcephaly and periventricular calcifications.

  • Herpesvirus latency permits reactivation after prior infection; reinfection with another CMV strain is also possible. Reactivation is a nonprimary infection, not a primary infection.

  • Immune evasion by CMV allows persistent infection and dissemination to multiple fetal organs.

  • Placental infection impairs nutrient and oxygen exchange, contributing to intrauterine growth restriction (IUGR).

InvolvementDetails
Organs

Central nervous system involvement causes neurological deficits such as microcephaly and sensorineural hearing loss.

Liver involvement manifests as hepatosplenomegaly and elevated liver enzymes in congenital infection.

Tissues

Placental tissue is a key site of viral transmission from mother to fetus in congenital infection.

Brain tissue is affected by viral cytopathic effects leading to microcephaly and calcifications.

Cells

Monocytes serve as reservoirs for latent cytomegalovirus and facilitate viral dissemination.

T lymphocytes are critical for controlling cytomegalovirus infection through cell-mediated immunity.

Chemical Mediators

Interferon-gamma is important for activating macrophages to control cytomegalovirus replication.

Tumor necrosis factor-alpha contributes to inflammation and tissue damage in congenital infection.

Treatments


Pharmacological Treatments

  • Ganciclovir

    • Mechanism:
      • Guanosine analogue activated initially by CMV UL97 kinase, then cellular kinases. Its triphosphate inhibits viral DNA polymerase and DNA synthesis; UL97 or polymerase mutations can confer resistance.

    • Side effects:
      • Neutropenia/myelosuppression; frequent CBC monitoring is essential

      • Anemia

      • Thrombocytopenia

      • Renal toxicity or accumulation with impaired renal clearance; monitor renal function

    • Clinical role:
      • IV alternative for an infant who needs antiviral treatment but cannot reliably absorb enteral medication. Transition to oral valganciclovir when feasible; IV therapy is not inherently superior. Congenital CMV use is off-label and specialist-directed.

  • Valganciclovir

    • Mechanism:
      • Orally absorbed prodrug of ganciclovir; conversion by esterases provides ganciclovir, whose phosphorylated form inhibits viral DNA polymerase.

    • Side effects:
      • Neutropenia/myelosuppression; CBC monitoring is essential

      • Anemia

      • Thrombocytopenia

      • Gastrointestinal upset; also monitor liver and renal function during therapy

    • Clinical role:
      • Preferred oral therapy for moderate/severe congenital CMV disease, including CNS involvement: typically 6 months, started promptly and before 13 weeks of age under current AAP guidance. For isolated sensorineural hearing loss, a 6-week course may be offered after specialist discussion; evidence is less certain. Mild disease is individualized. No routine treatment for infection with normal hearing and no disease. Use is off-label in the US.

Non-pharmacological Treatments

  • Supportive care including management of hearing loss with hearing aids or cochlear implants.

  • Provide repeated hearing assessment and developmental surveillance throughout childhood, with ophthalmology/neurology and early intervention according to findings. Antiviral treatment does not remove this follow-up need.

  • Early intervention programs for developmental delays.

Prevention


Pharmacological Prevention

  • Do not give valganciclovir routinely as neonatal prophylaxis. Antivirals treat selected infants with established congenital disease or hearing loss; asymptomatic infection with normal hearing is not treated outside research.

  • No licensed vaccine is currently available for congenital CMV prevention.

  • Antenatal antivirals are not routine US prophylaxis; suspected maternal/fetal infection requires maternal-fetal-medicine consultation. Some international protocols differ, so pregnancy treatment should follow specialist guidance rather than neonatal regimens.

Non-pharmacological Prevention

  • Hygiene measures such as handwashing reduce maternal CMV exposure during pregnancy.

  • Routine maternal CMV serologic screening is not recommended in the United States. Targeted evaluation follows suspected infection or fetal findings; a serostatus result alone does not predict fetal injury.

  • Reduce contact with young children's saliva/urine: wash hands after diaper changes, avoid sharing utensils/food and avoid kissing on the mouth. These measures reduce exposure without requiring avoidance of children.

  • Prenatal ultrasound may detect concerning abnormalities but does not prevent infection or exclude it when normal. Specialist evaluation may include appropriately timed amniotic-fluid PCR.

Outcome & Complications


Complications

  • Progressive sensorineural hearing loss is a major long-term complication.

  • Neurodevelopmental impairment including intellectual disability and motor deficits occurs in severe cases.

  • Vision loss from chorioretinitis can cause permanent blindness.

  • Seizure disorders may develop due to CNS scarring.

  • Thrombocytopenic bleeding can cause serious hemorrhagic events.

Short-term Sequelae Long-term Sequelae
  • Jaundice and hepatosplenomegaly often resolve with supportive care but indicate acute systemic infection.

  • Thrombocytopenia may cause bleeding requiring platelet transfusions.

  • Seizures may occur during the neonatal period due to encephalitis.

  • Feeding difficulties and failure to thrive are common in the neonatal phase.

  • Permanent sensorineural hearing loss is the most common chronic sequela.

  • Neurodevelopmental disability is especially associated with symptomatic CNS disease; it is not inevitable in all survivors, and many infected infants develop normally.

  • Visual impairment from retinal scarring can cause lifelong disability.

  • Microcephaly and cerebral palsy result from prenatal brain injury.

  • Epilepsy may develop as a chronic neurological complication.

Differential Diagnoses


Congenital Infections (Cytomegalovirus - HHV-5) versus Toxoplasmosis

Congenital Infections (Cytomegalovirus - HHV-5)

Toxoplasmosis

Classically periventricular calcifications, with possible ventriculomegaly and white-matter/developmental abnormalities.

Congenital toxoplasmosis classically combines intracranial calcifications, hydrocephalus and chorioretinitis. Multiple ring-enhancing lesions are the classic reactivation pattern in an immunocompromised host, not the defining congenital pattern.

Urine CMV PCR within 21 days; confirm positive saliva PCR with urine collected within that window.

Infant Toxoplasma IgM/IgA and serial IgG, with reference-laboratory interpretation and PCR as appropriate; maternal antibodies and false negatives complicate testing. Prenatal amniotic-fluid PCR addresses fetal infection.

Double-stranded DNA virus human herpesvirus 5 (CMV)

Intracellular protozoan parasite Toxoplasma gondii

Congenital Infections (Cytomegalovirus - HHV-5) versus Rubella

Congenital Infections (Cytomegalovirus - HHV-5)

Rubella

Urine CMV PCR within 21 days; confirm positive saliva PCR with urine collected within that window. CMV IgM is not a reliable diagnostic substitute.

Rubella IgM and RT-PCR, interpreted with clinical/exposure context; unlike maternal IgG, infant IgM supports infant infection, but false-positive/negative results require care.

Periventricular calcifications, sensorineural hearing loss and petechiae are classic clues.

Cataracts, PDA or peripheral pulmonary artery stenosis, and sensorineural hearing loss suggest congenital rubella.

Maternal CMV infection, often asymptomatic, during pregnancy

Maternal rubella infection during first trimester

Congenital Infections (Cytomegalovirus - HHV-5) versus Herpes Simplex Virus (HSV) Congenital Infection

Congenital Infections (Cytomegalovirus - HHV-5)

Herpes Simplex Virus (HSV) Congenital Infection

Infection acquired in utero; many infants are well at birth and some develop delayed hearing loss.

Rare intrauterine HSV presents at birth with congenital abnormalities. Most neonatal HSV is instead acquired intrapartum and presents during the first weeks.

Urine CMV PCR within 21 days; confirm positive saliva PCR with urine collected within that window.

Evaluate suspected neonatal HSV with lesion/surface specimens, blood and CSF HSV PCR as indicated. A negative early CSF PCR does not always exclude CNS disease.

Petechiae, jaundice, hepatosplenomegaly and periventricular calcifications.

Intrauterine HSV may cause skin scars/lesions, eye abnormalities and CNS injury. Peripartum neonatal HSV causes skin/eye/mouth, CNS or disseminated disease; vesicles may be absent.

Congenital Infections (Cytomegalovirus - HHV-5) versus Syphilis

Congenital Infections (Cytomegalovirus - HHV-5)

Syphilis

Urine CMV PCR within 21 days; confirm positive saliva PCR with urine collected within that window.

Interpret infant quantitative RPR/VDRL relative to maternal titers, maternal treatment and examination. A fourfold higher infant titer supports infection, but its absence does not exclude it. Passive maternal treponemal IgG makes neonatal treponemal tests unreliable confirmation.

Sensorineural hearing loss, petechiae and periventricular calcifications.

Early congenital syphilis may cause snuffles, rash and periostitis/osteochondritis. Hutchinson teeth are a late manifestation, not a neonatal sign.

Maternal CMV infection during pregnancy

Maternal untreated syphilis during pregnancy

Congenital Infections (Cytomegalovirus - HHV-5) versus Zika Virus Congenital Infection

Congenital Infections (Cytomegalovirus - HHV-5)

Zika Virus Congenital Infection

Periventricular calcifications with ventriculomegaly

Severe microcephaly with calcifications predominantly in the cortical-subcortical junction

Sensorineural hearing loss and petechiae

Arthrogryposis and severe microcephaly

Urine CMV PCR within 21 days; confirm positive saliva PCR with urine collected within that window.

For suspected congenital Zika, obtain infant serum NAAT/IgM and urine NAAT with public-health guidance. Interpret timing, exposure and phenotype together; negative tests do not definitively exclude congenital Zika syndrome.